Transient foamy virus vector production by adenovirus vectors

Gene Therapy

Volumn 11, Issue 3, 2004, Pages 310-316

  Russell, R A ^a   Vassaux, G ^a   Martin Duque, P ^a   McClure, M O ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Adenovirus; Gene therapy; Hybrid vectors; Prototype foamy virus

Indexed keywords

ADENOVIRUS VECTOR; CELL DNA; GAG PROTEIN; GENOMIC DNA; GREEN FLUORESCENT PROTEIN; PHOTOPROTEIN; POL PROTEIN; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ADENOVIRUS; ANIMAL; ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE CASSETTE; GENE EXPRESSION; GENE TRANSFER; GENE VECTOR; GENETIC CODE; GENETIC TRANSDUCTION; GENETICS; HELPER VIRUS; IN VITRO STUDY; METABOLISM; NONHUMAN; PHYSIOLOGY; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPUMA VIRUS; STRUCTURAL GENE; TARGET CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS HYBRID; VIRUS INFECTION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS TYPING;

ADENOVIRIDAE; ANIMALS; CELL LINE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELPER VIRUSES; LUMINESCENT PROTEINS; PLASMIDS; SPUMAVIRUS; TRANSDUCTION, GENETIC; TRANSGENES; VIRUS INTEGRATION;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; HUMAN SPUMARETROVIRUS; RNA VIRUSES; SPUMAVIRUS; VECTORS;

EID: 1242341275     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302177     Document Type: Article

References (56)

1. Yoshida Y, Emi N, Hamada H. VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem Biophys Res Commun 1997; 232: 379-382.
2. Feng M et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997; 15: 866-870.
3. Bilbao G et al. Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 1997; 11: 624-634.
4. Ramsey WJ et al. Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors. Biochem Biophys Res Commun 1998; 246: 912-919.
5. Lin X. Construction of new retroviral producer cells from adenoviral and retroviral vectors. Gene Therapy 1998; 5: 1251-1258.
6. Reynolds PN, Feng M, Curiel DT. Chimeric viral vectors - the best of both worlds? Mol Med Today 1999; 5: 25-31.
7. Duisit G, Salvetti A, Moullier P, Cosset FL. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum Gene Ther 1999; 10: 189-200.
8. Caplen NJ. Gene therapy: different strategies for different applications. American Society of Gene Therapy: First Annual Meeting, Seattle, Washington, USA, 28-31 May 1998. Mol Med Today 1998; 4: 374-375.
9. Zheng C, Baum BJ, Iadarola MJ, O'Connell BC. Genomic integration and gene expression by a modified adenoviral vector. Nat Biotechnol 2000; 18: 176-180.
10. Murphy SJ et al. Novel integrating adenoviral/retroviral hybrid vector for gene therapy. Hum Gene Ther 2002; 13: 745-760.
11. Chester J et al. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol 2002; 20: 256-263.
12. Bergau et al. Improved retrovirus titres from adeno/retro hybrids by complexing adenovirus components vectors with the polycation DEAE dextran. European Society of Gene Therapy Annual Meeting. Antibes, France, 12th-16th October 2002.
13. Soifer H et al. A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol Ther 2002; 5 (Part 1): 599-608.
14. Kubo S, Mitani K. A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. J Virol 2003; 77: 2964-2971.
15. Maher BA. Gene therapy trials hit obstacle. Scientist 2002; 16: 26.
16. Check E. A tragic setback. Nature 2002; 420: 116-118.
17. Schweizer M et al. Simian foamy virus isolated from an accidentally infected human individual. J Virol 1997; 71: 4821-4824.
18. Heneine W et al. Identification of a human population infected with simian foamy viruses. Nat Med 1998; 4: 403-407.
19. Stancek D, Gressnerova M. A viral agent isolated from a patient with subacute thyroditis de Quervain type. Acta Virol 1974; 18: 365.
20. Cameron KR, Birchall SM, Moses MA. Isolation of foamy virus from patient with dialysis encephalopathy. Lancet 1978; 2: 796.
21. Lagaye S et al. Human spumaretrovirus-related sequences in the DNA of leukocytes from patients with Graves disease. Proc Natl Acad Sci USA 1992; 89: 10070-10074.
22. Mahnke C et al. Human spumavirus antibodies in sera from African patients. Arch Virol 1992; 123: 243-253.
23. Cow JW et al. Search for retrovirus in the chronic fatigue syndrome. J Clin Pathol 1992; 45: 1058-1061.
24. Wick G et al. Possible role of human foamy virus in Graves' disease. Intervirology 1993; 35: 101-107.
25. Lycke J et al. Human spumaretrovirus antibody reactivity in multiple sclerosis. J Neurol 1994; 241: 204-209.
26. Schweizer M, Turek R, Reinhardt M, Neumann-Haefelin D. Absence of foamy virus DNA in Graves' disease. AIDS Res Hum Retroviruses 1994; 10: 601-605.
27. Heneine W et al. Absence of evidence for human spumaretrovirus sequences in patients with Graves' disease. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 99-101.
28. Hill CL, Bieniasz PD, McClure MO. Properties of human foamy virus relevant to its development as a vector for gene therapy. J Gen Virol 1999; 80 (Part 8): 2003-2009.
29. Bieniasz PD, Weiss RA, McClure MO. Cell cycle dependence of foamy retrovirus infection. J Virol 1995; 69: 7295-7299.
30. Russell DW, Miller AD. Foamy virus vectors. J Virol 1996; 70: 217-222.
31. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
32. Yang S et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 1999; 10: 123-132.
33. Riggs JL, McAllister RM, Lennette EH. Immunofluorescent studies of RD-114 virus replication in cell culture. J Gen Virol 1974; 25: 21-29.
34. Gluzman Y. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 1981; 23: 175-182.
35. He TC et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
36. Russell RA et al. The R region found in the human foamy virus long terminal repeat is critical for both Gag and Pol protein expression. J Virol 2001; 75: 6817-6824.
37. Pietschmann T et al. Foamy virus capsids require the cognate envelope protein for particle export. J Virol 1999; 73: 2613-2621.
38. Heinkelein M et al. Improved primate foamy virus vectors and packaging constructs. J Virol 2002; 76: 3774-3783.
39. Vousden KH, Jat PS. Functional similarity between HPV16E7, SV40 large T and adenovirus E1a proteins. Oncogene 1989; 4: 153-158.
40. Barbosa MS et al. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv-40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 1990; 9: 153-160.
41. Harada S, Yanagi K. Amino acid sequence homology of Epstein-Barr virus nuclear antigen-2 to adenovirus E1A, human papilloma virus-16 E7 and SV40 large T antigen in the functional domains for growth transformation. Oncogene 1991; 6: 461-462.
42. Lee I, Barton JK. A distinct intron-DNA structure in simian virus 40 T-antigen and adenovirus 2 E1A genes. Biochemistry 1993; 32: 6121-6127.
43. Mazzarelli JM, Atkins GB, Geisberg JV, Ricciardi RP. The viral oncoproteins Ad5 E1A, HPV16 E7 and SV40 TAg bind a common region of the TBP-associated factor-110. Oncogene 1995; 11: 1859-1864.
44. Becker TC et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 1994; 43: 161-189.
45. Ali M et al. No evidence of antibody to human foamy virus in widespread human populations. AIDS Res Hum Retroviruses 1996; 12: 1473-1483.
46. Channon KM et al. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function. Circ Res 1998; 82: 1253-1262.
47. Harui A, Suzuki S, Kochanek S, Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999; 73: 6141-6146.
48. Achong BG, Mansel PWA, Epstein MA, Clifford P. An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst 1971; 46: 299-302.
49. Achong BG, Mansel PW, Epstein MA. A new human virus in cultures from a nasopharyngeal carcinoma. J Pathol 1971; 103: 18.
50. Weiss RA. Foamy retroviruses. A virus in search of a disease [news]. Nature 1988; 333: 497-498.
51. Svenningsson A et al. No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis. Ann Neurol 1992; 32: 711-714.
52. Herchenroder O et al. Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV). Virology 1994; 201: 187-199.
53. Herchenroder O et al. Infectious proviral clones of chimpanzee foamy virus (SFVcpz) generated by long PCR reveal close functional relatedness to human foamy virus. Virology 1995; 214: 685-689.
54. Bieniasz PD et al. A comparative study of higher primate foamy viruses, including a new virus from a gorilla. Virology 1995; 207: 217-228.
55. Trobridge G, Vassilopoulos G, Josephson N, Russell DW. Gene transfer with foamy virus vectors. Methods Enzymol 2002; 346: 628-648.
56. Darquet AM et al. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Therapy 1997; 4: 1341-1349.